SD-06
CAY-30686-25 25 mg
Data Sheet: 
SDS:
SDS:
CAS
271576-80-8
Formulation
A solid
Purity
≥98%
MW
397,858
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
An inhibitor of p38α MAPK (IC50 = 0.016 µM); selective for p38α over p38β, p38γ, and p38δ MAPKs (IC50s = 0.677, >100, and >100 µM, respectively), as well as a panel of 54 additional kinases (IC50s = >3 µM for all); inhibits LPS-induced TNF-α, IL-6, and IL-1β release from primary human monocytes (IC50s = 79.4, 106.9, and 105.9 nM, respectively); decreases IL-1β-induced production of PGE2 in patient-derived RASFs (IC50 = 96.2 nM); reduces carrageenan-induced paw swelling and hyperalgesia in rats at 30 mg/kg; reduces the incidence of arthritis in a mouse model of collagen-induced arthritis; protects against joint and bone destruction in a rat model of streptococcal cell wall-induced arthritis
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
